LifeSemantics Obtains Patent for AI Solution Predicting Prostate Cancer Onset and Recurrence

LifeSemantics exterior [Photo by LifeSemantics]

[Asia Economy Reporter Chunhee Lee] LifeSemantics announced on the 22nd that it has acquired two patents related to artificial intelligence (AI) solutions for predicting the onset and recurrence of prostate cancer.

The patents include ▲a prostate cancer treatment planning system using predictive data and ▲a deep learning-based prostate cancer recurrence prediction system using time-series examination data. These inventions were developed during the ‘Doctor Answer 1.0’ project, supported by the Ministry of Science and ICT and the National IT Industry Promotion Agency, specifically in the development of ‘Prostate Cancer Staging and Recurrence Prediction Software.’

Confirming the final stage (병기, disease stage) of prostate cancer takes several weeks, during which there is a high possibility of cancer metastasizing to other organs. According to a 2021 survey by the Korean Society of Urologic Oncology, one in two prostate cancer patients in Korea was diagnosed at stage 3 or later. Additionally, the 2019 cancer registry statistics showed that 33.9% of prostate cancer patients were found to have cancer spread to other organs.

LifeSemantics plans to shorten the confirmation of the final prostate cancer stage by up to eight weeks through AI-based staging and recurrence prediction technology, helping establish treatment plans and blocking early metastasis and spread of prostate cancer. The prostate cancer treatment planning system using predictive data predicts the T stage of prostate cancer and lymph node metastasis status using only primary examination data without secondary tests, supporting clinicians in establishing systematic preoperative treatment plans. The ‘deep learning-based prostate cancer recurrence prediction system using time-series examination data’ models regularly collected test data such as prostate-specific antigen (PSA) tests before and after prostate cancer diagnosis and surgery as time-series data and applies it to a deep learning neural network to predict recurrence in prostate cancer surgery patients. Thanks to the deep learning characteristic where accuracy improves with an increasing amount of high-quality preprocessed data, it is expected to greatly assist medical professionals in predicting prostate cancer recurrence.

With this patent acquisition, LifeSemantics aims to advance precision medical AI technology and expand the scope of disease prediction. Currently developing AI software for predicting prostate cancer onset under the Gangwon Precision Medical Regulatory Free Zone project, LifeSemantics plans to build a one-stop AI solution system that supports the entire clinical process from prostate cancer onset to metastasis and recurrence.

Dongbeom Kim, head of research planning at LifeSemantics, said, “Prostate cancer ranks third in cancer incidence among Korean men after lung and stomach cancer, showing a rapid annual increase of about 12%. Since 94% of all patients are aged 60 or older, a precision staging prediction system that enables proactive treatment planning is urgently needed. We will focus more on advancing medical AI technology to supply software tailored to the characteristics of prostate cancer patients, primarily to domestic medical institutions.”